Search

Your search keyword '"Yan-Wen Zhang"' showing total 3 results
Start Over Author "Yan-Wen Zhang" Journal fitoterapia
3 results on '"Yan-Wen Zhang"'

1. Hypouricemic effect of allopurinol are improved by Pallidifloside D based on the uric acid metabolism enzymes PRPS, HGPRT and PRPPAT

Author

Yi He, Hong-Gang Li, Xi Zhang, Yan-Wen Zhang, Samantha Anderson, Jun Zhang, Pi-Yong Hou, Shu-Qing Wang, and Xiao-Hui Wu

Subjects
Male, musculoskeletal diseases, 0301 basic medicine, Hypoxanthine Phosphoribosyltransferase, Xanthine Oxidase, congenital, hereditary, and neonatal diseases and abnormalities, Allopurinol, Hyperuricemia, Pharmacology, PC12 Cells, Mice, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Drug Discovery, Ribose-Phosphate Pyrophosphokinase, medicine, Animals, RNA, Messenger, Transaminases, chemistry.chemical_classification, nutritional and metabolic diseases, Drug Synergism, Pallidifloside D, General Medicine, Metabolism, Saponins, medicine.disease, Rats, Uric Acid, Gout, 030104 developmental biology, Enzyme, Gene Expression Regulation, Biochemistry, chemistry, Hypoxanthine-guanine phosphoribosyltransferase, 030220 oncology & carcinogenesis, Smilax, Uric acid, medicine.drug
Abstract

Allopurinol is a commonly used medication to treat hyperuricemia and its complications. Pallidifloside D, a saponin glycoside constituent from the total saponins of Smilax riparia, had been proved to enhanced hypouricemic effect of allopurinol based on uric acid metabolism enzyme XOD. In this study, we evaluated whether Pallidifloside D (5mg/kg) enhanced hypouricemic effect of allopurinol (5mg/kg) related to others uric acid metabolism enzymes such as PRPS, HGPRT and PRPPAT. We found that, compared with allopurinol alone, the combination of allopurinol and Pallidifloside D significantly up-regulated HGPRT mRNA expression and down-regulated the mRNA expression of PRPS and PRPPAT in PC12 cells (all P

Published
2016
Full Text
View/download PDF

2. Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice

Author

Fei Yu, Shu-Qing Wang, Chao Mi, Yi He, Jun Zhang, Pi-Yong Hou, Yan-Wen Zhang, Samantha Anderson, and Xiao-Hui Wu

Subjects
Male, musculoskeletal diseases, Xanthine Oxidase, congenital, hereditary, and neonatal diseases and abnormalities, Allopurinol, Glucose Transport Proteins, Facilitative, Organic Anion Transporters, Hyperuricemia, Urine, Pharmacology, Gout Suppressants, Mice, chemistry.chemical_compound, Organic Anion Transport Protein 1, Drug Discovery, medicine, Smilax riparia, Animals, Glycosides, Xanthine oxidase, Molecular Structure, business.industry, nutritional and metabolic diseases, Drug Synergism, Pallidifloside D, General Medicine, Saponins, medicine.disease, Uric Acid, Gout, Disease Models, Animal, Oxonic Acid, chemistry, Creatinine, Smilax, Uric acid, business, medicine.drug
Abstract

Pallidifloside D, a saponin glycoside constituent from the total saponins of Smilax riparia, had been proved to be effective in hyperuricemic control. Allopurinol is a commonly used medication to treat hyperuricemia and its complications. In this study, we evaluated whether Pallidifloside D could enhance allopurinol's effects by decreasing the serum uric acid level in a hyperuricemic mouse model induced by potassium oxonate. We found that, compared with allopurinol alone, the combination of allopurinol and Pallidifloside D significantly decreased the serum uric acid level and increased the urine uric acid level (both P0.05), leading to the normalized serum and urine uric acid concentrations. Data on serum, urine creatinine and BUN supported these observations. Our results showed that the synergistic effects of allopurinol combined with Pallidifloside D were linked to the inhibition of both serum and hepatic xanthine oxidase (XOD), the down-regulation of renal mURAT1 and mGLUT9, and the up-regulation of mOAT1. Our data may have a potential value in clinical practice in the treatment of gout and other hyperuricemic conditions.

Published
2015
Full Text
View/download PDF

3. Three new acetylated benzyl-beta-resorcylate glycosides from Cassia obtusifolia

Author

Jinlan Ruan, Xiao-Hui Wu, Hong-Quan Duan, De-An Guo, Jian-Shi Lou, Zhi-Yuan Wu, Yan-Wen Zhang, Jun Zhang, and V.C. Yang

Subjects
Pharmacology, chemistry.chemical_classification, biology, Molecular Structure, Stereochemistry, Cassia, Glycoside, General Medicine, Hep G2 Cells, biology.organism_classification, Antineoplastic Agents, Phytogenic, chemistry.chemical_compound, chemistry, Acetylation, Drug Discovery, Benzyl Compounds, Seeds, Organic chemistry, Humans, Glycosides, Benzoic acid
Abstract

Three new acetylated benzyl-beta-resorcylate glycosides (1–3) were isolated from seeds of Cassia obtusifolia. Their structures were determined on the basis of the spectroscopic methods and physicochemical properties as 2-benzyl-4,6-dihydroxy benzoic acid-6-O-[2,6-O-diacetyl]-d-glucopyranoside (1), 2-benzyl-4,6-dihydroxy benzoic acid-6-O-[3,6-O-diacetyl]-d-glucopyranoside (2) and 2-benzyl-4, 6-dihydroxy benzoic acid-6-O-[4,6-O-diacetyl]-d-glucopyranoside (3), respectively.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results